Programmed death-ligand 1 expression in diffuse large B-cell lymphoma is associated with poor prognosis.

IF 2.3 4区 医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY International Journal of Biological Markers Pub Date : 2023-03-01 DOI:10.1177/03936155221149749
Esraa Al-Khateeb, Manal A Abbas, Majd B Khader, Maher A Sughayer
{"title":"Programmed death-ligand 1 expression in diffuse large B-cell lymphoma is associated with poor prognosis.","authors":"Esraa Al-Khateeb,&nbsp;Manal A Abbas,&nbsp;Majd B Khader,&nbsp;Maher A Sughayer","doi":"10.1177/03936155221149749","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Programmed death-ligand 1 (PD-L1) expression in some tumors has prognostic implications. This work aims at investigating PD-L1 expression in diffuse large B-cell lymphoma (DLBCL) and to study its association with clinicopathological variables.</p><p><strong>Methods: </strong>The study consisted of 75 DLBCL patients who were cared for at the King Hussein Cancer Center during the period 2015-2018. The expression of PD-L1 in tumor tissue was assessed by immunohistochemistry using the anti-human PD-L1 (Clone 22C3) monoclonal antibody. The correlation between gender, age, clinical stage, pre-treatment-LDH level, tumor location, response to therapy, overall and event-free survival with PD-L1 expression was studied.</p><p><strong>Results: </strong>Six patients were excluded from further analysis as they were in relapse at the time of tissue sampling. The tumor proportion score (TPS) was ≥1% in 16/69 (23.2%) of DLBCL cases while the combined positive score (CPS) at a cut-off of ≥20 was observed in 23/69 (33.3%) cases. No significant difference in PD-L1 expression was found between germinal center B-cell-like (GCB) and non-GCB subtypes. Similarly, no differences in PD-L1 expression (at CPS ≥20 and TPS ≥1) were found between different genders, age groups, clinical stages, tumor location, and patient response to therapy. However, base-line lactate dehydrogenase was significantly elevated in patients with PD-L1 CPS ≥20. The overall survival was not significantly different between PD-L1-positive and -negative groups. On the other hand, the median event-free survival was higher in either of the PD-L1 TPS or CPS negative groups at 107months each versus 54 months in the PD-L1 positive group of either category.</p><p><strong>Conclusions: </strong>PD-L1 expression can predict event-free survival in DLBCL cases and therefore poor prognosis.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"38 1","pages":"53-60"},"PeriodicalIF":2.3000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03936155221149749","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Programmed death-ligand 1 (PD-L1) expression in some tumors has prognostic implications. This work aims at investigating PD-L1 expression in diffuse large B-cell lymphoma (DLBCL) and to study its association with clinicopathological variables.

Methods: The study consisted of 75 DLBCL patients who were cared for at the King Hussein Cancer Center during the period 2015-2018. The expression of PD-L1 in tumor tissue was assessed by immunohistochemistry using the anti-human PD-L1 (Clone 22C3) monoclonal antibody. The correlation between gender, age, clinical stage, pre-treatment-LDH level, tumor location, response to therapy, overall and event-free survival with PD-L1 expression was studied.

Results: Six patients were excluded from further analysis as they were in relapse at the time of tissue sampling. The tumor proportion score (TPS) was ≥1% in 16/69 (23.2%) of DLBCL cases while the combined positive score (CPS) at a cut-off of ≥20 was observed in 23/69 (33.3%) cases. No significant difference in PD-L1 expression was found between germinal center B-cell-like (GCB) and non-GCB subtypes. Similarly, no differences in PD-L1 expression (at CPS ≥20 and TPS ≥1) were found between different genders, age groups, clinical stages, tumor location, and patient response to therapy. However, base-line lactate dehydrogenase was significantly elevated in patients with PD-L1 CPS ≥20. The overall survival was not significantly different between PD-L1-positive and -negative groups. On the other hand, the median event-free survival was higher in either of the PD-L1 TPS or CPS negative groups at 107months each versus 54 months in the PD-L1 positive group of either category.

Conclusions: PD-L1 expression can predict event-free survival in DLBCL cases and therefore poor prognosis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
弥漫性大b细胞淋巴瘤的程序性死亡配体1表达与不良预后相关。
背景:程序性死亡配体1 (PD-L1)在某些肿瘤中的表达具有预后意义。本研究旨在探讨PD-L1在弥漫性大b细胞淋巴瘤(DLBCL)中的表达,并研究其与临床病理变量的关系。方法:该研究包括2015-2018年期间在侯赛因国王癌症中心接受治疗的75例DLBCL患者。采用抗人PD-L1(克隆22C3)单克隆抗体免疫组化检测肿瘤组织中PD-L1的表达。研究性别、年龄、临床分期、治疗前ldh水平、肿瘤部位、治疗反应、总生存期和无事件生存期与PD-L1表达的相关性。结果:6例患者因在组织取样时处于复发期而被排除在进一步分析之外。16/69例(23.2%)DLBCL患者肿瘤比例评分(TPS)≥1%,23/69例(33.3%)患者联合阳性评分(CPS)≥20。生发中心b细胞样(GCB)和非GCB亚型之间PD-L1表达无显著差异。同样,PD-L1表达(CPS≥20和TPS≥1)在不同性别、年龄组、临床分期、肿瘤位置和患者对治疗的反应之间也没有差异。然而,在PD-L1 CPS≥20的患者中,基线乳酸脱氢酶显著升高。pd - l1阳性组和阴性组的总生存率无显著差异。另一方面,PD-L1 TPS组或CPS阴性组的中位无事件生存期均高于PD-L1阳性组的中位无事件生存期,分别为107个月和54个月。结论:PD-L1表达可以预测DLBCL患者无事件生存期,因此预后较差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
International Journal of Biological Markers
International Journal of Biological Markers 医学-生物工程与应用微生物
CiteScore
4.10
自引率
0.00%
发文量
43
期刊介绍: IJBM is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers. IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment.
期刊最新文献
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial. CircLPHN3 correlates with prognosis in colorectal cancer and regulates cellular processes by targeting miR-142-5p. Prognostic value of miR-190a-5p in renal cell cancer and its regulatory effect on tumor progression. Circulating exosomal miRNA-451 as an effective diagnostic biomarker and prognostic indicator for multiple myeloma. Inflammatory markers related to survival in breast cancer patients: Peru.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1